Clinical trial

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary…

NCT00325403 · United Therapeutics, Industry · Completed

Key facts

NCT number NCT00325403
Title FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Official title A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension
Lead sponsor United Therapeutics, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Pulmonary Hypertension
Intervention type Drug, Other
Interventions Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Enrollment 349
Start date Oct 1, 2006
Primary completion Apr 1, 2011
Completion Apr 1, 2011
First posted May 12, 2006
Last update posted Jan 3, 2024
Countries Austria, Belgium, Canada, China, France, India, Israel, Italy, Mexico, Netherlands, Poland, Puerto Rico and 1 more

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies